NewsRelease
ReviewArticle Cites Cleanascite™ To Analyze Lipid-based Nanocarriers
MONMOUTHJUNCTION, NJ,December3, 2020 -- Biotech Support Group reports on a recent review articledescribing the simplicity and efficiency of their lipid clearancesample preparation technology to confirm the conjugation of a peptideligand to a nanoparticle surface.The citation is:
Guyon,Léna, Anne-Claire Groo, and Aure̝lie Malzert-Fre̝on. "RelevantPhysicochemical Methods to Functionalize, Purify, and CharacterizeSurface-Decorated Lipid-Based Nanocarriers." MolecularPharmaceutics (2020).
Surfacefunctionalization of lipid-based nanocarriers (LBNCs) with targetingligands has attracted huge interest in the field of nanomedicines fortheir ability to overcome some physiological barriers and theirpotential to deliver an active molecule to a specific target withoutcausing damage to healthy tissues. In this review article, theauthors state the use of Cleanascite™ in the analysis of LBNCs;“Conjugation of PPACK (a short chain peptide that inhibitsthrombin) to liposomes was investigated through HPLC quantificationof uncoupled peptide recovered from the supernatant aftercentrifugation of predialysis PPACK-liposomes mixed with Cleanascite™lipid adsorption reagent. This indirect quantification was performedat a wavelength of 215 nm (detection of amide bond).”
“Hereis another reference showing the versatility of Cleanascite™ as ageneral delipidation reagent for many varied applications thatrequire a precise binding selection of lipid-based macromoleculesfrom the non-lipid bound protein/peptide mixture” states SwapanRoy, Ph.D., President and Founder of Biotech Support Group.
Formore information visit: Cleanascite™Lipid Removal Reagent and Clarification,at
https://www.biotechsupportgroup.com/Lipid-Removal-s/316.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal.From these innovations, the company has acquired knowledgebase andbiomarker intellectual property assets that support discoveries ofprotein markers from blood, with special emphasis on early detectionand personalized medical decisions for cancer patients. For moreinformation, go tohttp://www.biotechsupportgroup.com.
ForBusiness Development, contact:MatthewKuruc 732-274-2866, [email protected]